F.D.A. Regulators Say Benefits of Pfizer’s Pediatric Shot Outweighs Risks

The findings could add momentum for the agency’s authorization of the dose for 5- to 11-year-olds, perhaps as soon as next week. Get updates on the pandemic.

F.D.A. Regulators Say Benefits of Pfizer’s Pediatric Shot Outweighs Risks
The findings could add momentum for the agency’s authorization of the dose for 5- to 11-year-olds, perhaps as soon as next week. Get updates on the pandemic.